Pomegranate Health advertises compounded semaglutide at $119/month and tirzepatide at $149/month, significantly lower than PlexusDx's month-to-month rates. We compare pricing structures, service models, and documented fee clarity across both platforms.

Brello Health's three-month prepaid plans cost $399 for semaglutide and $499 for tirzepatide, delivering lower annual costs than PlexusDx three-month commitments. The trade-off: upfront payment versus month-to-month billing.

OrderlyMeds advertises a two-month starter rate for compounded semaglutide that works out to $74.50 per month equivalent, then $149 monthly. PlexusDx charges $189 month-to-month with no starter period.

AltRx advertises steep promotional discounts on compounded semaglutide and tirzepatide through September 5, 2026, but individual reports allege unexpected billing practices and standard rates are unknown. PlexusDx publishes one flat rate with no promotion cycles or prepayment options.

Whether MEDVi is worth its recurring price depends on how much of the bundled program you will use. This guide lists what MEDVi documents beyond the medication, separates included access from service promises, works the cost over three, six and twelve billing cycles, and shows where a leaner program such as PlexusDx may fit instead.

Fridays leads with unlimited support and $0 lab fees. Zealthy separates medication from membership. PlexusDx offers lower verified pricing and published multi-month rates. This evidence-based comparison normalizes costs and flags verification gaps so you can choose with confidence.

Found offers standard-dose GLP-1s with optional insurance billing and 12-month prepaid plans; Remedy publishes only a microdose option at $189/month. We compare structures, pricing, and fit across both programs plus PlexusDx alternatives.